Table 5.
The comparison between guideline documents and product assessments.
| Guidance documents/products | Pharmacology |
Toxicology |
||||||
|---|---|---|---|---|---|---|---|---|
| Pharmacodynamics | Biodistribution/Pharmacokinetics | Mechanical property | Validation of clinical evaluation | Local toxicity | Systemic toxicity | Tumorigenicity | Genotoxicity | |
| Guideline of the EU | ✔a | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ |
| Guideline of the US | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | – |
| Guideline of Japan | ✔ | ✔ | ✔ | – | ✔ | ✔ | ✔ | – |
| Carticel® | ✔ | ✔ | – | – | ✔ | – | – | – |
| ChondroCelect™ | ✔ | ✔ | – | – | ✔ | ✔ | ✔ | – |
| JACC | ✔ | –b | – | – | ✔ | ✔ | ✔ | ✔ |
| MACI® | ✔ | ✔ | ✔ | ✔ | ✔ | ✔ | – | ✔ |
EU, European Union; US, United States; JP, Japan.
✔: Described.
–: Not described.